Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

April 2013

P&T Committee Update 


At a March 4, 2013 meeting, Harvard Pilgrim’s Pharmacy & Therapeutics Committee reviewed several drugs and decided the following:

P&T Committee Review and Decisions

Name Indication Decision
Onfi
(clobazam) 
Onfi is used along with other medications to treat seizures associated with Lennox-Gastaut syndrome, a severe, difficult-to-treat form of childhood-onset epilepsy.  Prior authorization required. Moved to Tier 2
(Tier 3 for 4-Tier formulary)
Latuda
(lurasidone) 
Latuda is an atypical antipsychotic used to treat schizophrenia in adults.  Moved to Tier 2
(Tier 3 for 4-Tier formulary)
Kapvay
(clonidine ER) 
Kapvay, an extended release formulation of clonidine, is used to treat Attention-Deficit Hyperactivity Disorder (ADHD).   Continued coverage at Tier 3
(Tier 4 for 4-Tier formulary)
Brilinta
(ticagrelor)
Brilinta is used in conjunction with aspirin for secondary prevention of thrombotic events in patients with acute coronary syndrome. Brilinta is in the same therapeutic category as clopidigrel (Plavix). Moved to Tier 2
(Tier 3 for 4-Tier formulary)
Picato
(ingenol mebutate) 
Picato is a topical gel used to treat actinic keratosis.  Moved to Tier 2 (Tier 3 for 4-Tier formulary)

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

New Massachusetts Mandate for Oral Chemotherapies

Growing the Medicare Advantage Network

CLINICIAN CORNER

Complex Case Management Services

Disease Management Programs that Reinforce Physician Treatment Plans

P&T Committee Update

Motivational Interviewing in the Primary Care Setting

OFFICE ASSISTANT

Updated Pricing for Molecular Pathology Codes

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network and Product Development

Joann Peck,
Manager, Network Planning and Administration

Annmarie Dadoly,
Editor

Kristin Edmonston,
Production Coordinator